ARTICLE | Targets & Mechanisms
Genocea's cautionary tale: avoid inhibitory neoantigens in vaccines
Genocea shows targeting inhibitor neoantigens can abrogate vaccine-mediated protection
November 21, 2019 7:13 PM UTC
Genocea’s SITC presentations bolstered its case for screening out inhibitory neoantigens from cancer vaccines by suggesting the peptides play a role in checkpoint inhibitor resistance and promote disease progression.
One of the keys to designing effective personalized cancer vaccines is the selection of neoantigens that, when presented on MHC molecules, elicit potent antitumor immune responses. ...